window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

ViCentra

  • Drug Delivery & Formulation,Healthcare leadership,Market Access & Commercialization,Medical devices,Movers & Shakers

    ViCentra appoints Reman McDonagh as vice president, global marketing to support Kaleido scale-up

    ViCentra has appointed Reman McDonagh as vice president, global marketing [...]

    January 29, 2026
  • Medical devices,Metabolic Diseases,Partnerships & Funding

    ViCentra expands Series D financing to $98m to support Kaleido insulin patch pump rollout

    ViCentra has expanded its Series D financing round to $98m, [...]

    January 8, 2026
  • Digital Health,Medical devices,Patient Centricity,Technology and platforms

    ViCentra raises $85M to scale manufacturing and accelerate market penetration of Kaleido insulin patch pump

    ViCentra, a European medical device company redefining insulin delivery for [...]

    September 8, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Currax highlights peer-reviewed review supporting combination approaches in obesity treatment
    Categories: Obesity, Pharmaceuticals and therapeutics, Research & Development
  • MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD
    Categories: Clinical Development, Clinical studies, Hematology, Regulatory Affairs, Research & Development
  • Symbiosis expands QC capabilities with new 30°C stability chamber
    Categories: CDMOs & Manufacturing, Facilities and infrastructure, Manufacturing, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top